Multiparametric MRI of prostate cancer: An update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 5, 2013, Pages 1035-1054

  Hegde, John V ^a,b   Mulkern, Robert V ^a,c   Panych, Lawrence P ^a   Fennessy, Fiona M ^a,d   Fedorov, Andriy ^a   Maier, Stephan E ^a   Tempany, Clare M C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

diffusion weighted imaging; dynamic contrast enhanced imaging; magnetic resonance spectroscopy; multiparametric MRI; prostate cancer; T2 weighted imaging

Indexed keywords

BARIUM SULFATE; CONTRAST MEDIUM; FLUOROCARBON;

CANCER CELL; CANCER INVASION; CELL DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIFFUSION WEIGHTED IMAGING; ELECTRON SPIN RESONANCE; IMAGE ANALYSIS; INFLAMMATORY CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; QUANTITATIVE ANALYSIS; REVIEW; SCAR FORMATION; SIGNAL NOISE RATIO; SMOOTH MUSCLE FIBER; T2 WEIGHTED IMAGING; TUMOR BLEEDING;

FORECASTING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84876492235     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23860     Document Type: Review

References (107)

1. Prasad SM, Gu X, Lipsitz SR, Nguyen PL, Hu JC,. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer 2011; 118: 1260-1270.
2. Poon PY, McCallum RW, Henkelman MM, et al. Magnetic resonance imaging of the prostate. Radiology 1985; 154: 143-149.
3. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987; 162: 331-336.
4. Martin JF, Hajek P, Baker L, Gylys-Morin V, Fitzmorris-Glass R, Mattrey RR,. Inflatable surface coil for MR imaging of the prostate. Radiology 1988; 167: 268-270.
5. Schnall MD, Lenkinski RE, Pollack HM, Imai Y, Kressel HY,. Prostate: MR imaging with an endorectal surface coil. Radiology 1989; 172: 570-574.
6. Tempany CM, Rahmouni AD, Epstein JI, Walsh PC, Zerhouni EA,. Invasion of the neurovascular bundle by prostate cancer: evaluation with MR imaging. Radiology 1991; 181: 107-112.
7. Melki PS, Mulkern RV, Panych LP, Jolesz FA,. Comparing the FAISE method with conventional dual-echo sequences. J Magn Reson Imaging 1991; 1: 319-326.
8. Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994; 192: 47-54.
9. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT,. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243: 28-53.
10. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-461.
11. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814.
12. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66.
13. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H,. MR imaging of the prostate in clinical practice. MAGMA 2008; 21: 379-392.
14. Masterson TA, Touijer K,. The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA 2008; 21: 371-377.
15. Umbehr M, Bachmann LM, Held U, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2009; 55: 575-590.
16. Rouviere O, Hartman RP, Lyonnet D,. Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 2006; 16: 276-284.
17. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994; 193: 703-709.
18. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195.
19. Noworolski SM, Crane JC, Vigneron DB, Kurhanewicz J,. A clinical comparison of rigid and inflatable endorectal-coil probes for MRI and 3D MR spectroscopic imaging (MRSI) of the prostate. J Magn Reson Imaging 2008; 27: 1077-1082.
20. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E,. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236: 903-910.
21. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255: 89-99.
22. Rosen Y, Bloch BN, Lenkinski RE, Greenman RL, Marquis RP, Rofsky NM,. 3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn Reson Med 2007; 57: 898-904.
23. Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L,. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int 2009; 104: 621-627.
24. Scheenen TW, Heijmink SW, Roell SA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 2007; 245: 507-516.
25. Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW,. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009; 44: 572-576.
26. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K,. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31: 625-631.
27. Miao H, Fukatsu H, Ishigaki T,. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007; 61: 297-302.
28. Kim CK, Park BK, Kim B,. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. AJR Am J Roentgenol 2010; 194: W33-37.
29. Metens T, Miranda D, Absil J, Matos C,. What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? Eur Radiol 2012; 22: 703-709.
30. Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Invest Radiol 2011; 46: 301-306.
31. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-494.
32. Wang J, Qiu M, Yang QX, Smith MB, Constable RT,. Measurement and correction of transmitter and receiver induced nonuniformities in vivo. Magn Reson Med 2005; 53: 408-417.
33. Wicks DA, Barker GJ, Tofts PS,. Correction of intensity nonuniformity in MR images of any orientation. Magn Reson Imaging 1993; 11: 183-196.
34. Fan A, Wells WM, Fisher JW, et al. A unified variational approach to denoising and bias correction in MR. Inf Process Med Imaging 2003; 18: 148-159.
35. Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 2010; 29: 1310-1320.
36. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995; 195: 385-390.
37. Turner R, Le Bihan D, Chesnick AS,. Echo-planar imaging of diffusion and perfusion. Magn Reson Med 1991; 19: 247-253.
38. Padhani AR,. Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging 2011; 11 (Spec No A): S27-37.
39. Burdette JH, Elster AD, Ricci PE,. Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology 1999; 212: 333-339.
40. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology 2010; 255: 485-494.
41. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249: 900-908.
42. Bourne R, Kurniawan N, Cowin G, Sved P, Watson G,. 16 T diffusion microimaging of fixed prostate tissue: preliminary findings. Magn Reson Med 2011; 66: 244-247.
43. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006; 24: 563-568.
44. Storas TH, Gjesdal KI, Gadmar OB, Geitung JT, Klow NE,. Prostate magnetic resonance imaging: multiexponential T2 decay in prostate tissue. J Magn Reson Imaging 2008; 28: 1166-1172.
45. Roebuck JR, Haker SJ, Mitsouras D, Rybicki FJ, Tempany CM, Mulkern RV,. Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging 2009; 27: 497-502.
46. Liney GP, Knowles AJ, Manton DJ, Turnbull LW, Blackband SJ, Horsman A,. Comparison of conventional single echo and multi-echo sequences with a fast spin-echo sequence for quantitative T2 mapping: application to the prostate. J Magn Reson Imaging 1996; 6: 603-607.
47. Gibbs P, Tozer DJ, Liney GP, Turnbull LW,. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 2001; 46: 1054-1058.
48. Chan I, Wells W, 3rd, Mulkern RV, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys 2003; 30: 2390-2398.
49. Issa B,. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002; 16: 196-200.
50. Yoshizako T, Wada A, Uchida K, et al. Apparent diffusion coefficient of line scan diffusion image in normal prostate and prostate cancer-comparison with single-shot echo planner image. Magn Reson Imaging 2011; 29: 106-110.
51. Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 2009; 29: 1360-1366.
52. Shukla-Dave A, Hricak H, Eberhardt SC, et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology 2004; 231: 717-724.
53. Tamada T, Sone T, Toshimitsu S, et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging 2008; 27: 552-556.
54. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
55. Sourbron SP, Buckley DL,. On the scope and interpretation of the Tofts models for DCE-MRI. Magn Reson Med 2011; 66: 735-745.
56. Tofts PS, Berkowitz B, Schnall MD,. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995; 33: 564-568.
57. Parker GJ, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006; 56: 993-1000.
58. Meng R, Chang SD, Jones EC, Goldenberg SL, Kozlowski P,. Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer. Acad Radiol 2010; 17: 520-525.
59. Bottomley PA,. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987; 508: 333-348.
60. Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-133.
61. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A,. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 2004; 52: 80-88.
62. Mulkern RV, Panych LP,. Echo planar spectroscopic imaging. Concepts Magn Reson 2001; 13: 213-237.
63. Chen AP, Cunningham CH, Ozturk-Isik E, et al. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging 2007; 25: 1288-1292.
64. Pruessmann KP, Weiger M, Scheidegger MB, Boesiger P,. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 1999; 42: 952-962.
65. Kyriakos WE, Panych LP, Kacher DF, et al. Sensitivity profiles from an array of coils for encoding and reconstruction in parallel (SPACE RIP). Magn Reson Med 2000; 44: 301-308.
66. Sodickson DK,. Tailored SMASH image reconstructions for robust in vivo parallel MR imaging. Magn Reson Med 2000; 44: 243-251.
67. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB,. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002; 16: 451-463.
68. Mulkern R, Bowers J,. Density matrix calculations of AB spectra from multipulse sequences: quantum mechanics meets In vivo spectroscopy. Concepts Magn Reson 1994; 6: 1-23.
69. Scheenen TWJ, Gambarota G, Weiland E, et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005; 53: 1268-1274.
70. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ,. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198: 795-805.
71. Kim JK, Kim DY, Lee YH, et al. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil. Magn Reson Imaging 1998; 16: 1281-1288.
72. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213: 473-480.
73. Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn Reson Imaging 1999; 17: 755-765.
74. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708.
75. Shukla-Dave A, Hricak H, Moskowitz C, et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007; 245: 499-506.
76. Thomas MA, Lange T, Velan SS, et al. Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo. MAGMA 2008; 21: 443-458.
77. Kumar V, Jagannathan NR, Kumar R, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed 2007; 20: 505-511.
78. Poon CS, Henkelman RM,. Practical T2 quantitation for clinical applications. J Magn Reson Imaging 1992; 2: 541-553.
79. Westphalen AC, Reed GD, Vinh PP, Sotto C, Vigneron DB, Kurhanewicz J,. Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer. J Magn Reson Imaging 2012; 36: 430-437.
80. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV,. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458-463.
81. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H,. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology 2008; 246: 168-176.
82. Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, Horsman A,. In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging 1997; 15: 1177-1186.
83. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257: 715-723.
84. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495.
85. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-888.
86. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 2007; 189: 849.
87. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17: 1498-1509.
88. Scherr MK, Seitz M, Muller-Lisse UG, Ingrisch M, Reiser MF, Muller-Lisse UL,. MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer. Eur J Radiol 2010; 76: 359-366.
89. Franiel T, Ludemann L, Rudolph B, et al. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 2009; 252: 101-108.
90. Franiel T, Ludemann L, Rudolph B, Lutterbeck E, Hamm B, Beyersdorff D,. Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation. AJR Am J Roentgenol 2010; 194: 675-681.
91. Giusti S, Caramella D, Fruzzetti E, Lazzereschi M, Tognetti A, Bartolozzi C,. Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D (1)H MR spectroscopic imaging: correlation with pathologic findings. Abdom Imaging 2010; 35: 757-763.
92. Scheenen TW, Futterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol 2011; 46: 25-33.
93. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol 2011; 60: 1074-1080.
94. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189: 323-328.
95. Lim HK, Kim JK, Kim KA, Cho KS,. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study. Radiology 2009; 250: 145-151.
96. Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 2009; 252: 449-457.
97. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259: 775-784.
98. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-458.
99. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011; 107: 1411-1418.
100. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186: 1818-1824.
101. Delongchamps NB, Beuvon F, Eiss D, et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis 2011; 14: 232-237.
102. Casciani E, Polettini E, Bertini L, et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007; 32: 796-802.
103. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008; 246: 480-488.
104. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA,. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 30: 327-334.
105. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009; 56: 981-987.
106. Arani A, Plewes D, Krieger A, Chopra R,. The feasibility of endorectal MR elastography for prostate cancer localization. Magn Reson Med 2011; 66: 1649-1657.
107. Li S, Chen M, Wang W, et al. A feasibility study of MR elastography in the diagnosis of prostate cancer at 3.0T. Acta Radiol 2011; 52: 354-358.